Shannon Westin, MD, MPH, FASCO

“It’s not a magic diet or a trendy diet. It is essentially saying eat vegetables and fruit and whole grains and cut out processed food,” says our Dr. Jennifer McQuade in @WSJ. She presented results of this high-fiber diet trial at @ASCO. #ASCO25 Read more:…

A high fiber dietary intervention significantly improved response to immunotherapy in patients with melanoma receiving immune checkpoint blockade therapy. Our postdoctoral fellow Dr. Yufan Simon Qiu shared results at #ASCO25. Learn more: bit.ly/4mGk4pO @NazliDizman…

#ASCO25 GSK FIRST presented today - I am proud of this trial as the US PI and the contribution of our sites and grace of our patients in participating. But- statistical significance did not translate to clinical relevance so we must say - no role for CPI in FL EOC.

There is a whole Toy Story-inspired movie to be written about the afterlives of discarded conference posters: once so beloved, then so quickly tossed aside 😢 #ASCO25

At #ASCO25, Katherine Hutcheson, Ph.D., presented results from the Phase IV PRO-ACTIVE trial, which compared timing and intensity of swallow therapy for patients with head and neck cancer receiving radiation. No meaningful difference was found between reactive and proactive…

Smiles all around at #ASCO25 as Dr. Jennifer Litton and Dr. Uday Popat spent time with the canine therapy dogs. Thank you to @ASCO and these four-legged friends for bringing smiles to the meeting floor. #EndCancer @JenniferLitton

New data from the CADENZA study shows pivekimab sunirine (PVEK) led to a 70% CR + CRc rate in frontline BPDCN with a manageable safety profile. Presented by Dr. Naveen Pemmarju at #ASCO25. #EndCancer bit.ly/45E62i9 @doctorpemm

Dr. Eric Singhi shares his excitement about the lung cancer research being presented at #ASCO25. Hear how this year’s meeting highlights the continued momentum in advancing the field and improving patient outcomes. #EndCancer @lungoncdoc

My husband, the incredible Lymphoma specialist @Lymphoma_Doc - has been a tireless advocate for our patients and @ASCO - check out his master class on how to advocate as a physician....Definitely required viewing!!! #ASCO25 #advocacy shorturl.at/zMxCy

Catching up on #ASCO25 - terrific discussion by @TiansterZhang @utswcancer on abstracts from #SamerSrourMD @MDAndersonNews, @DrChoueiri @DanaFarberNews, @motzermd @MSKCancerCenter & @VivekNarayanMD @PennCancer. Varied topics all eloquently addressed! Thanks for citing the…

🔔Make sure to check our study!! @ASCO #ASCO25 ⭐️#HighFiber (HF) #diet to modulate microbiome and outcomes in #immunotherapy in #Melanoma ✅ORR: ⬆️HF 77% Cntrl 29% ✅No significant GI related or Immune related AEs with HF diet ✅Cutaneous adverse events⬇️ w HF ✅ impressive EFS…

Really interesting data to help predict pneumonitis in patients treated with ADCs- will need to explore this further in Gyn Ca #ASCO25 #gyncsm

🧬 Pharmacogenomics may guide safer, personalized ADC use. Congratulations Emre et al.! 👏👏👏 @ASCO @DanaFarber @DrChoueiri @PTarantinoMD @stolaney1 @OncoBellmunt @ReneeSaliby @OncoAlert #ASCO25 @AnkaraUni @Ankaratip1945 @harvardmed @BrighamWomens

So exciting to do a deep dive on translational work in DUO-E to help potentially guide therapy in #EndometrialCancer - can we potentially select therapy based on presence of ctDNA?? Would be great to do a trial to further explore this!!! #ASCO25 #gyncsm

🙌 We demonstrated increased clearance of ctDNA (positive test to negative test over 2 cycles) during maintenance with olaparib 💡this indicates tumor kill in the maintenance phase for MMRp #EndometrialCancer #ASCO25 #gyncsm

Addition of IMNN-001 (novel IL12 immunostimulatory cytokine) to neoadjuvant chemotherapy in advanced stage #ovariancancer 👍66% AE - higher abdominal pain, cytopenias -but very few d/c 🤩Trend toward OS benefit 🤔Will be confirmed in ongoing phase 3 study #ASCO25 #gyncsm

Phase 2 study of lenvatinib and pembrolizumb is active in clear cell #ovariancancer !!! 👍 36.7% response rate 🙌 PFS 10.9 months 🤩 57% dose reduction (expected w this regimen) Awesome story in a rare tumor population!!! #ASCO25 #gyncsm

Phase 2 study of pembrolizumab added to chemoradiation therapy in #vulvarcancer w cisplatin yields 75% response rate and manageable AE #ASCO25 #gyncsm

Nothing is possible without mentorship and sponsorship. Thank you @ShannonWestin for believing in this budding clinical trialist and advocating for me (and so many other trainees) to be in the room where it happens! #ASCO25